NasdaqCM - Nasdaq Real Time Price USD

Bluejay Diagnostics, Inc. (BJDX)

Compare
0.1439 +0.0010 (+0.71%)
As of 10:24 AM EDT. Market Open.
Loading Chart for BJDX
DELL
  • Previous Close 0.1429
  • Open 0.1390
  • Bid --
  • Ask --
  • Day's Range 0.1353 - 0.1440
  • 52 Week Range 0.1310 - 48.8000
  • Volume 419,155
  • Avg. Volume 2,123,814
  • Market Cap (intraday) 2.381M
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) --
  • EPS (TTM) -43.0400
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 256.00

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

bluejaydx.com

10

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BJDX

View More

Performance Overview: BJDX

Trailing total returns as of 9/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BJDX
98.53%
S&P 500
19.63%

1-Year Return

BJDX
99.61%
S&P 500
32.09%

3-Year Return

BJDX
99.98%
S&P 500
22.80%

5-Year Return

BJDX
99.98%
S&P 500
22.80%

Compare To: BJDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BJDX

View More

Valuation Measures

Annual
As of 9/23/2024
  • Market Cap

    2.36M

  • Enterprise Value

    -5.27M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.27

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -58.51%

  • Return on Equity (ttm)

    -125.25%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -9.4M

  • Diluted EPS (ttm)

    -43.0400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.06M

  • Total Debt/Equity (mrq)

    5.12%

  • Levered Free Cash Flow (ttm)

    -5.49M

Research Analysis: BJDX

View More

Company Insights: BJDX

Research Reports: BJDX

View More

People Also Watch